Succeeder(688338)2023-04-20 16:00Financial Performance - The net profit attributable to shareholders for 2022 was RMB 104,114,179.36, with a distributable profit of RMB 346,243,513.10 as of December 31, 2022[5]. - The company plans to distribute a cash dividend of RMB 2.6 per 10 shares, totaling RMB 21,228,480.00, which represents 20.39% of the net profit for the year[5]. - The company's operating revenue for 2022 was CNY 228.81 million, a decrease of 4.63% compared to CNY 239.92 million in 2021[23]. - Net profit attributable to shareholders increased by 6.93% to CNY 104.11 million in 2022, up from CNY 97.37 million in 2021[23]. - The net cash flow from operating activities was CNY 100.56 million, a decline of 6.39% from CNY 107.42 million in 2021[23]. - The company's total assets at the end of 2022 reached CNY 1.61 billion, an increase of 8.64% from CNY 1.48 billion at the end of 2021[23]. - Basic earnings per share rose to CNY 1.28 in 2022, reflecting a growth of 7.56% from CNY 1.19 in 2021[24]. - The company's total revenue for the year reached ¥228,222,764.00, representing a 62.37% increase compared to the previous year[98]. - The sales revenue from coagulation products increased by 72.19% year-on-year, amounting to ¥131,736,202.93[97]. Research and Development - The company is investing in R&D, allocating 150 million RMB towards the development of new technologies and products[15]. - The R&D expenditure as a percentage of operating revenue increased to 7.40% in 2022, up from 6.34% in 2021[24]. - The company invested ¥16,938,833.60 in R&D in 2022, an increase of 11.40% year-on-year[36]. - The company has 21 ongoing R&D projects and has obtained multiple medical device registration certificates and patents during the reporting period[36]. - The company has developed 15 core technologies, including blood rheology measurement and coagulation diagnostic testing platforms, and holds 32 patents, of which 10 are invention patents[50]. - The company is actively developing new diagnostic products, including lupus anticoagulant testing kits, with several projects in the clinical trial phase[61]. - The company has made significant advancements in the development of monoclonal antibodies for D-Dimer detection, which will improve diagnostic accuracy[73]. Market Expansion and Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[15]. - Market expansion plans include entering two new international markets by the end of the next fiscal year[15]. - The company is considering strategic acquisitions to enhance its product offerings and market presence[15]. - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain[15]. - The company plans to enhance customer acquisition for coagulation products to stabilize revenue amidst declining demand for other products[98]. - The company is focusing on expanding its market presence through the introduction of new products and technologies, aiming for increased competitiveness in the medical device sector[75]. Operational Efficiency - The gross margin improved to 45%, up from 42% in the previous year, indicating better cost management[15]. - The company aims to reduce operational costs by 8% through efficiency improvements in the supply chain[147]. - The operating cost was ¥86,177,055.03, a decrease of 10.08%, with the main business operating cost at ¥85,870,046.34, down 9.67%[94]. - The total gross margin for the year was 62.37%, with a year-on-year decrease of 4.27%[98]. Governance and Compliance - The company maintains a robust governance structure, ensuring compliance with laws and regulations while protecting shareholder rights[133]. - The company emphasizes transparent communication with investors and stakeholders, ensuring timely and accurate information disclosure[136]. - The company’s governance practices comply with relevant laws and regulations, ensuring the legality and validity of shareholder meeting resolutions[140]. - The company has not faced any major legal or regulatory discrepancies in its governance practices[137]. Environmental and Social Responsibility - The company is committed to sustainable development and environmental protection, implementing practices to reduce waste and promote green initiatives[188]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[193]. - The company operates in compliance with environmental regulations, ensuring that wastewater, noise, and solid waste are properly managed[200]. - The company emphasizes sustainable development while protecting the rights of shareholders, creditors, and employees[190]. Human Resources - The number of R&D personnel increased to 48, representing 17.58% of the total workforce, up from 40 and 15.04% respectively in the previous period[80]. - Total compensation for R&D personnel reached 946.14 million, compared to 809.33 million in the prior period[80]. - The company has a comprehensive compensation policy that includes monthly salaries, year-end bonuses, and various allowances, ensuring internal equity and external competitiveness[176]. - The average salary of core technical personnel was reported at 826.42, indicating a competitive compensation structure within the industry[145].